Q-omics provides the consensus-scored RPL23AP16 profile across patient tissues and cancer cell-line models. RPL23AP16 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in MESO. Additionally, RPL23AP16 RNA expression shows 6,198 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight MESO, and LUAD as cancer lineages where RPL23AP16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.